Abstract| Volume 51, SUPPLEMENT 1, S4-S5, March 2015

Download started.


ITOC2 – 012. Neoadjuvant immune checkpoint blockade for pancreatic cancer prevents local tumour recurrence through tissue resident antitumoural CD8+ CD103+ T cells

      This paper is only available as a PDF. To read, Please Download here.
      Pancreatic ductal adenocarcinoma exhibits strong metastatic disease at early stages of primary tumour formation. Despite resection of the primary tumour the prognosis for patients is dismal. 80% of the patients develop local recurrence.
      Therefore, we analysed immune checkpoint blockade using therapeutic PD1-antibody in a neoadjuvant approach.
      We generated a transgenic mouse model for formation of a single resectable primary tumour at pancreatic tail with distant metastases. This autochthonous growing tumour was induced by local in situ electroporation of the pancreas with the sleeping beauty transposon system for genetic modification and transformation of pancreatic cells.
      Blockade of the inhibitory receptor PD1 resulted in activation and expansion of tissue resident antitumoural CD8+ CD103+ T cells within the pancreas. This T cells were accumulated only at the site of the primary tumour and could not act systemically. The investigation of the neoadjuvant approach indeed revealed prevention of local tumour recurrence after resection of the primary tumour. Thereby, distant metastases were not affected. Further findings displayed that distant metastases could be targeted by NK cells, while primary tumour of the pancreas was targeted by CD 8 cells.
      In conclusion, we could identify tissue resident antitumoural CD8 T cells after PD1 therapy. Surgical intervention using our transgenic mouse model resulted in prevention of local tumour recurrence after resection of the primary tumour.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect